Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2016 02:15 ET | Source: Neovacs, Inc.

Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)

PARIS and BOSTON, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the U.S. Food...
November 23, 2016 12:00 ET | Source: Neovacs, Inc.

Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs

Agreement addresses future production needs of IFNα, key component of IFN Kinoid1 PARIS and BOSTON, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active...
November 15, 2016 02:15 ET | Source: Neovacs, Inc.

Neovacs Acquires Interferon Alpha Manufacturing Technology From AMEGABIOTECH

PARIS and BOSTON, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced an agreement with...
November 07, 2016 02:15 ET | Source: Neovacs, Inc.

Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE)

PARIS and BOSTON, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) (PEA-eligible SMEs), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced...
November 03, 2016 02:30 ET | Source: Neovacs, Inc.

Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

PARIS and BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at...
October 12, 2016 10:18 ET | Source: Neovacs, Inc.

Neovacs Signs a Cooperation Agreement With the Department Immunology of Diabetes at the Reputed Hospital Cochin in Paris

PARIS, Oct. 12, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV) (PEA-PME eligible), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a...
September 30, 2016 13:45 ET | Source: Neovacs, Inc.

Half-Year Results 2016 and Update on Operational Development

Cash position significantly strengthened by successful capital increasePhase IIb clinical trial in lupus expanded into the United States PARIS, Sept. 30, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext...
August 30, 2016 02:15 ET | Source: Neovacs, Inc.

Neovacs to present at two major Investor Conferences:

PARIS and BOSTON, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced CEO Miguel Sieler will...
May 17, 2016 02:15 ET | Source: Neovacs, Inc.

Neovacs to attend ChinaBio® Event May 18 & 19, 2016

PARIS and BOSTON, May 17, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the...
April 28, 2016 11:40 ET | Source: Neovacs, Inc.

Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States

PARIS and BOSTON, April 28, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that the Company has...